This article is more than 5 years old. Information may no longer be current.

Investigational drug for androgenetic alopecia safe, tolerable

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 2 trial results for SM04554, an investigational drug for androgenetic alopecia, were presented at the 74^th Annual Meeting of the American Academy of Dermatology, the drug’s manufacturer, Samumed, announced in a press release.

The multicenter, randomized, double-masked, vehicle-controlled trial included 302 patients. Patients received treatment once a day for 90 days. Posttreatment follow-up lasted 45 days.

Trial results demonstrated that SM04554 was safe, effective and well-tolerated. The treatment group showed an increase in hair count and hair density, and the vehicle group showed a decrease in both measures. At the end of the trial period, the treatment group showed a 0.15% higher increase in hair density and count compared to the vehicle group.